GERN Stock Analysis: Buy, Sell, or Hold?
GERN - Geron Corp
$1.42
-0.08 (-5.33%)
▼
5d:
-1.39%
30d:
+29.09%
90d:
-14.97%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
22d
Smart Money Distribution
None View Scanner →
Strength: 6.7/10
Get Alerted When GERN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GERN shows positive signals but monitor for confirmation. Market pricing in 2.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: GERN shows positive signals but monitor for confirmation. Market pricing in 2.2% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GERN is currently trading at $1.42, which is considered slightly high relative to its 30-day fair value range of $1.16 to $1.44. The stock's valuation (Forward PE: 21.9) is in line with its historical norms (20.5). At these levels, the market is pricing in 2.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GERN is in a strong downtrend. Immediate support is located at $1.26, while resistance sits at $1.62. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: GERN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+139.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GERN is in a strong downtrend. Immediate support is located at $1.26, while resistance sits at $1.62. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: GERN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.40 (+139.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$1.16 -
$1.44
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 139.4% below Wall St target ($3.40)
- NEUTRAL: Market pricing in 2.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$1.16 -
$1.44
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$1.26
Resistance Level
$1.62
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.85
Wall Street Target
$3.40
(+139.4%)
Revenue Growth (YoY)
30.9%
Profit Margin
-34.3%
Valuation Premium vs History
+2.2% premium
PE vs Historical
21.9 vs 20.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.2%
(market-implied from PE analysis)
1-Year Target
$1.45
(+2%)
2-Year Target
$1.48
(+4%)
3-Year Target
$1.52
(+7%)
3-Yr Target (if PE normalizes)
(PE: 22→21)
PE COMPRESSION
$1.42
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 13, 2026 6:02 PM ET
Data refreshes hourly during market hours. Next update: 7:02 PM
Data refreshes hourly during market hours. Next update: 7:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GERN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
Advanced GERN Option Strategies
Professional options setups generated by AI based on today's GERN price and gamma walls.
